Abstract:Supplementary Figure S6. (A-D) Histone deacetylase activity analysis of HDAC1 (A), HDAC2 (B), HDAC3 (C), and HDAC10 (D) in KG-1α and Kasumi-1 cells after treatments with CS055 (4 μM) and chiglitazar (16 μM) by HDAC Activity Assay kit. (E) Quantitative real-time PCR analysis of SLC7A11 mRNA levels in KG-1α and Kasumi-1 cells treated with CS055 and/or chiglitazar for 24 h. (F) Western blotting analysis of HDAC3 expression in KG-1α and Kasumi-1 cells treated with CS055 and/or chiglitazar for 24 h. (G) Western blotting analysis of HDAC3 expression in HDAC3 knockdown KG-1α and Kasumi-1 cells. (H) Western blotting analysis of HDAC3 expression in HDAC3, and HDAC3 mutant (H134A and H135A) overexpressed KG-1α and Kasumi-1 cells. Western blotting data was quantified and analyzed by Image J Soft. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Supplementary Figure 3 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

Supplementary Figure 4 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

Supplementary Figure 2 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Supplementary Figure S1 from Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition

Supplemental Figure S5 from Histone Deacetylase HDAC8 Promotes Insulin Resistance and Β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma

Supplementary Figure S2 from Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition

Supplemental Figure S4 from Histone Deacetylase HDAC8 Promotes Insulin Resistance and Β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma

Supplementary Figure 1 from CAAT/Enhancer Binding Protein Homologous Protein–Dependent Death Receptor 5 Induction is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells

Supplementary Figure 1 from HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components

Supplemental Figure S8 from Histone Deacetylase HDAC8 Promotes Insulin Resistance and Β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma

Supplementary Figure 2. from HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components

Supplementary Figure 3 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response Via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Figure S2 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma

Supplementary Figure S6 from Combinations of HDAC Inhibitor and PPAR Agonist Induce Ferroptosis of Leukemic Stem Cell–like Cells in Acute Myeloid Leukemia

Supplementary Figure Legends 1-4 from Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors

Supplementary Figure 2 from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy

Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Supplementary Figure 1 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer